BioSpace Global Roundup, Oct. 15
The Pharma Data
OCTOBER 14, 2020
Priothera will use the funds to progress the clinical development of mocravimod, a modulator of sphingosine 1 phosphate (S1P) receptors, to enhance the curative potential of allogeneic hematopoietic stem cell transplantation (HSCT) for treating AML. All jobs have been maintained and the workforce has grown from about 220 to 350.
52 
Let's personalize your content